Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Shock. 2015 Aug;44(2):128–136. doi: 10.1097/SHK.0000000000000386

Figure 1. Human neutrophils are induced by priming agents to release MMP-9.

Figure 1

A, Representative gelatin zymogram demonstrating increased MMP-9 activity in supernatants from human neutrophils purified from a healthy volunteer after treatment with either TNF α (20 ng/mL) or GM-CSF (24 ng/mL) for 30 or 60 minutes. B, Quantification of MMP-9 activity determined by zymography in supernatants of human neutrophils treated with priming agents compared to control. Data is expressed as mean ± SEM (n=3). C, Measurement of ROS production by human neutrophils determined by luminometry demonstrating that neutrophils treated only with TNF α (20 ng/mL) or GM-CSF (24 ng/mL) are not activated to produce ROS. Primed neutrophils are activated to produce ROS after treatment with the agonist fMLP (100 nM). Experiment performed in duplicate. Data is expressed as mean ± half range.